|
|
|
|
|
08.05.26 - 01:12
|
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly appointed president and chief executive officer, Shao-Lee Lin, M.D., Ph.D. The equity awards were made pursuant to the Company's 2026 Inducement Stock Incentive Plan and were unanimously approved by the independent directors of the Company as an inducement material to each new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
30.04.26 - 22:27
|
Cue Biopharma Announces $30 Million Private Placement (GlobeNewswire EN)
|
|
|
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement (the “PIPE financing”) for gross proceeds of approximately $30 million to Cue Biopharma, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions....
|
|
|
|
|
23.04.26 - 20:31
|
XFRA: Deletion of Instruments from Boerse Frankfurt - 23.04.2026 (XETRA)
|
|
|
The following instruments on Boerse Frankfurt do have their last trading day on 23.04.2026
Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.04.2026
ISIN Name
AU000000BMG3 BMG RESOURCES LTD
AU000000KAI5 KAIROS MINERALS
CA67054W1032 NUMINUS WELLNESS INC.
CA89624B3020 TRILLION ENERGY INTERNAT.
SE0015191739 CONSENSUS AS.MGM.B SK 5,-
US22978P1066 CUE BIOPHARM.INC. DL-,001
US25264R2076 DIAMOND HILL DL-,01
US84612H1068 SOW GOOD INC. DL -,001...
|
|
|
23.04.26 - 16:57
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
AU000000BMG3 BMG Resources Ltd. 23.04.2026 AU0000466021 BMG Resources Ltd. 24.04.2026 Tausch 1:1
AU000000KAI5 Kairos Minerals Ltd. 23.04.2026 AU0000466062 Kairos Minerals Ltd. 24.04.2026 Tausch 1:1
US22978P1066 Cue Biopharma Inc. 23.04.2026 US22978P2056 Cue Biopharma Inc. 24.04.2026 Tausch 30:1
US84612H1068 Sow Good Inc. 23.04.2026 US84612H3049 Sow Good Inc. 24.04.2026 Tausch 15:1
CA89624B3020 Trillion Energy International Inc. 23.04.2026 CA89624B5009 Trillion Energy International Inc. 24.04.2026 Tausch 5:1...
|
|
|
|
|
22.04.26 - 14:39
|
Cue Biopharma Announces 1-for-30 Reverse Stock Split (GlobeNewswire EN)
|
|
|
BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company's common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026....
|
|
|
08.04.26 - 14:03
|
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement (GlobeNewswire EN)
|
|
|
BOSTON, April 08, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage memory T cell subsets to deplete pathogenic B cells for the potential treatment of autoimmune and inflammatory diseases, today announced that it will receive a $7.5 million preclinical milestone payment under its collaboration and license agreement with Boehringer Ingelheim following Boehringer Ingelheim's selection and approval of its first compound for lead optimization. The Company expects to receive the payment in May 2026....
|
|
|
|
|
|
|
|
|
|
|
|
|
09.03.26 - 13:03
|
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026 (GlobeNewswire EN)
|
|
|
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced that it will deliver a poster presentation on the company's lead asset, CUE-401, at the World Immune Regulation Meeting (WIRM) being held March 11-14, 2026 in Davos, Switzerland. The presentation will include new in vitro data that demonstrate the therapeutic potential of CUE-401 to restore immune balance for the treatment of autoimmune and inflammatory diseases....
|
|
|
|
|
|
|
|
|
19.12.25 - 14:03
|
Cue Biopharma Announces Pricing of $10 Million Public Offering (GlobeNewswire EN)
|
|
|
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggregate of 17,857,143 shares of common stock. Each share of common stock (or pre-funded warrant to purchase shares of common stock in lieu thereof) and accompanying common stock warrant are being sold together at a combined public offering price of $0.28 (or $0.279, in the case of pre-funded warrants to purchase shares of common stock). The aggregate gross proceeds of the offering are expected to be approximately $10 million, before deducting underwriting discounts and commissions and other offering expens...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
